The EASL guidelines on the clinical management of hereditary cholestatic liver disease, published in 2024, suggest that genetic testing should be performed as early as possible in the diagnostic process after ruling out common causes. Along with a better understanding of the genes and proteins involved in biliary homeostasis and the increasing availability of genetic testing, more and more patients with adult-onset cholestasis are being tested for cholestasis genes that play a role in progressive intrahepatic familial cholestasis (PFIC).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Multiple sclerosis
Unexpected side effects when switching from natalizumab to a biosimilar
- Immunotherapy
Subcutaneously or intravenously?
- Work-related asthma
When the job leads to exacerbations
- Inoperable NSCLC
Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy
- De-escalation strategies
De-escalation strategies – less is more
- Pain and autism
Hurdles to pain treatment for autistic patients
- Advanced NSCLC
MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC
- Pathophysiological mechanisms and therapeutic perspectives